To learn more about Actineer and the clients EMED supports, visit Actineer’s website.
A New Era in Ac-225 Production
In recent years, EMED has developed a comprehensive suite of equipment to support the creation and processing of Actinium-225, a rare and powerful alpha-emitting isotope used in targeted alpha therapy (TAT) for cancer treatment. This equipment has been instrumental in enabling Actineer Inc., a joint venture between CNL and ITM Isotope Technologies Munich SE, to scale up industrial production of Ac-225. Actineer’s mission is to meet the growing global demand for this life-saving isotope, and their recent success in producing GMP-grade Ac-225 through cyclotron irradiation of Radium-226 marks a major milestone in cancer therapy innovation.